Novo Nordisk A/S
(NYSE : NVO)

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.41%164.930.7%$1445.32m
PFEPfizer Inc. 0.18%33.830.9%$1226.47m
BMYBristol-Myers Squibb Co. -0.70%62.351.0%$870.41m
MRKMerck & Co., Inc. 0.52%74.950.7%$828.25m
LLYEli Lilly & Co. -0.61%203.271.1%$823.19m
ABBVAbbVie, Inc. 0.34%108.961.9%$818.20m
AZNAstraZeneca Plc -0.64%49.781.2%$526.41m
GSKGlaxoSmithKline Plc -0.09%34.650.2%$268.57m
NVSNovartis AG -0.02%87.410.2%$202.61m
SNYSanofi -0.26%46.490.2%$169.71m
VTRSViatris, Inc. 0.72%15.410.0%$139.80m
VERUVeru, Inc. 0.13%15.170.0%$125.99m
VYNEVYNE Therapeutics, Inc. -1.79%8.240.0%$121.21m
CVACCureVac NV 1.92%100.050.0%$110.85m
NVONovo Nordisk A/S 0.83%72.830.1%$92.59m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.